Navigation Links
Spartan Bioscience Receives FDA Clearance for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs
Date:8/27/2013

Ottawa, Ontario (PRWEB) August 27, 2013

Spartan Bioscience today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of the Spartan RX CYP2C19 System. It provides genetic results in less than 60 minutes from a non-invasive cheek swab.

The automated system is indicated as an aid for clinicians to determine therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. These include some of the world’s most commonly prescribed drugs such as Plavix® (clopidogrel), Inderal® (propranolol), Celexa® (citalopram), and Losec® (omeprazole).

The sample-to-result system identifies CYP2C19*2, *3, and *17 variations from a patient’s cheek swab. The system’s ease of use and on-demand processing capability enable hospitals to generate time-critical results.

"The Spartan RX CYP2C19 System helps doctors treat patients faster with the most effective drugs,” said Paul Lem, M.D., CEO of Spartan Bioscience. “FDA clearance is a significant achievement for Spartan Bioscience. There is a tremendous opportunity for rapid DNA testing in the United States.”

About CYP2C19

The CYP2C19 enzyme metabolizes approximately 15 percent of all prescribed drugs, including important drug classes such as anti-platelet therapies (clopidogrel), beta blockers (propranolol), anti-depressants (citalopram), proton pump inhibitors (omeprazole), and anti-epileptics (phenytoin).(1) About 30 percent of Caucasians, 40 percent of Africans, and more than 50 percent of Asians and Indians carry CYP2C19 gene variants that reduce response to drugs metabolized by CYP2C19.(2,3,4,5) The CYP2C19*2 and *3 variants account for the majority of reduced drug metabolism. The CYP2C19*17 variant is associated with increased drug metabolism.

About Spartan Bioscience

Spartan Bioscience is the leader in on-demand DNA testing.(6) In the same way that mainf
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. First Point-of-Care DNA Test Submitted for FDA Clearance by Spartan Bioscience
2. Spartan Bioscience Announces 6,000-Patient Study of Personalized Medicine for Cardiac Stents
3. Seahorse Bioscience and the Cancer Research UK Beatson Institute Team Up Against Cancer
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
5. MD Biosciences Offers IL-23-Induced Psoriasis-Like Preclinical Model for Skin Inflammation
6. Sanguine BioSciences Announces Distribution Partnership with AMS Biotechnology
7. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
8. Flagship Biosciences Expands Digital Pathology with Pharmaceutical Biostatistics Services
9. Factor Bioscience Granted First U.S. Patent for RNA-Based Reprogramming Technology
10. Oxford University Press to publish BioScience journal starting in 2014
11. Neurocrine Biosciences Reports Second Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... next steps for its Oral Amphotericin B program.  ... in vitro work involving samples from ... plans to complete pre clinical studies and regulatory ... 1A clinical trial, utilizing approximately $700,000 of funding ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
(Date:10/20/2014)... Richardson, Texas (PRWEB) October 20, 2014 ... today announced that a team from Iowa State University ... * design contest. Using a Convey HC-2ex, the team’s ... than 14 times faster than the second place finisher. ... academic world embarked upon the month long challenge, using ...
(Date:10/20/2014)... , A major pan-European survey into the ... care has revealed changing trends in many important GI ... of healthcare services across the continent. The results of ... (UEG), have been announced today and led to calls ... of GI disorders across Europe ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... DIEGO, Oct. 31 Optimer Pharmaceuticals, Inc. (Nasdaq: ... from fidaxomicin,s North American phase 3 study at the ... America (IDSA) in Philadelphia, PA. , (Logo: ... of the Division of Infectious Diseases, Chair of the ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... today that the Company will host a conference call ... Thursday, November 5, 2009 to discuss its third quarter ... participate in the call, please dial 800-860-2442 (domestic) or ...
... Pa., Oct. 30 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: BJGP ) ("BMP ... , , -- Oppenheimer 20th Annual Healthcare Conference, to ... the Waldorf=Astoria hotel in New York. Management is scheduled, ... 3, and meet with, institutional investors ...
Cached Biology Technology:Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 2Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 3Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 4BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009 2BMP Sunstone Announces November Investor Conference Participation 2
(Date:10/14/2014)... sequenced the house fly genome for the first time, ... an insect that thrives in pathogen-rich dung piles and ... the journal Genome Biology , will increase understanding ... flies quickly adapt to resist insecticides, which could lead ... domestica) carry and transmit more than 100 human and ...
(Date:10/14/2014)... has discovered a new kind of stem cell that can ... liver blood vessels, according to a study published today in ... such a cell type contradicts current theory on how organs ... clues to origins of, and future treatment for, liver cancer., ... into a complex being made up of more than 200 ...
(Date:10/14/2014)... 14, 2014 – Scientists from The Scripps Research Institute ... Institutes of Health (NIH) to lead an investigation of ... disease in Africa. The study aims to understand how ... die, while others survive the inflection. , "The ... mechanism of how Lassa fever virus causes disease and ...
Breaking Biology News(10 mins):House fly genome reveals expanded immune system 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... President Ricardo Romo used the occasion of the dedication of ... on the Universitys 1604 Campus to announce an $822,000 gift ... For some time, we have wanted to create a lasting ... So, several months ago, we asked the Board of Regents ...
... Project for Ice Coring in Antarctica), one of the ... Networking Programmes, is one of this years winners of ... Research was awarded to three European teams for outstanding ... European Union on 12 March in Brussels. The EPICA ...
... computing communications platforms slated ... for delivery during ... Bulletin Board: CTHH), ( http://www.catcherinc.com ), a leading,provider of standards-based ... demanding application environments,today announced the Company has received an initial ...
Cached Biology News:UTSA receives $822,000 from Kleberg Foundation to enhance scientific research 2ESF's European ice core project EPICA receives prestigious Descartes Prize 2ESF's European ice core project EPICA receives prestigious Descartes Prize 3Catcher Holdings Inc. Lands Contract for Initial Deployments at Nine Homeland Security and State Government Agencies 2Catcher Holdings Inc. Lands Contract for Initial Deployments at Nine Homeland Security and State Government Agencies 3Catcher Holdings Inc. Lands Contract for Initial Deployments at Nine Homeland Security and State Government Agencies 4
... Trap is specifically designed for efficient ... as DMSO and DMF in the ... refrigeration system set at -5 o ... DMSO, while completely eliminating the risk ...
Thermo Forma provides an array of accessory Racks for the Cryo/CryoPlus 16" Diameter storage system. To maximise inventory capacity a Jumbo Arrowhead configuration is recommended. You may choose betw...
... combine high durability and capacity with unequalled ... mechanism prevents vibration, allowing the unit to ... other part, from the large rubber block ... aluminum platform is designed to last through ...
The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
Biology Products: